COMPANY INTELLIGENCEWhat the linked records show
MedtechLedger currently links 7 FDA records to the applicant name Kestra Medical Technologies, Inc.. It includes 1 original PMA approval. 1 entry is a PMA supplement. 5 entries are 30-day notices. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from Jul 27, 2021 to Nov 4, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code MVK appears in 7 of the 7 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P200037, with 7 linked entries. Follow the parent application and its dated supplements to distinguish the original device scope from later changes. 3 linked filings have a current plain-language explanation checked against the recorded FDA decision.
Applicant mailing address recorded by FDA: 3933 Lake Washington Blvd. NE, Suite 200, Kirkland, WA, 98033. Recorded on P200037/S022, decision dated Nov 4, 2026.
Device categories in this collection
Wearable Automated External Defibrillator.
Changes described in PMA records
The FDA recorded a 30-day notice decision, coded OK30, dated 2026-11-04 for supplement P200037/S022 to the ASSURE Wearable Cardioverter Defibrillator (WCD) System, a wearable automated external defibrillator (product code MVK, cardiovascular specialty) held by Kestra Medical Technologies, Inc. The supplement type is a 30-Day Notice and the recorded reason is a process change affecting manufacturer, sterilizer, packager or supplier.
The recorded statement describes the addition of a second-generation welding system. This entry documents that manufacturing process change within the existing PMA, not a new approval of the whole WCD system, and the source provides no detail on which components the welding system affects, what validation was reviewed, or the basis for the OK30 coding. No supporting documents were included in the source data, so those specifics remain unknown.
The source does not state whether the change alters device performance, labeling or clinical use, and no clinical or legal conclusion should be drawn from the decision code alone.
FDA approval-order wording
addition of second-generation welding system
Nov 4, 2026 · 30-Day NoticeThe FDA record for P200037/S021 identifies a 30-day notice for the ASSURE Wearable Cardioverter Defibrillator (WCD) System, product code MVK, submitted by Kestra Medical Technologies, Inc. The stated purpose is an updated workflow for the post-wear data transfer process, filed under the supplement reason process change affecting a manufacturer, sterilizer, packager or supplier.
The S021 suffix ties this filing to the original PMA P200037, but it is a supplement, not a new approval of the whole system. The notice describes a manufacturing and process update only; it does not establish safety or clinical effectiveness. The record does not specify which workflow steps, data pathways or components changed, leaving that detail absent.
FDA approval-order wording
an updated workflow for the post-wear data transfer process
Sep 28, 2026 · 30-Day NoticeFDA’s recorded scope: relocation of manufacturing equipment to new supplier facility
Jul 16, 2026 · 30-Day NoticeFDA’s recorded scope: updates to the tester used for final acceptance
Apr 14, 2026 · 30-Day NoticeFDA’s recorded scope: approval of software version 5.1.
Mar 6, 2026 · Normal 180 Day TrackSubsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.